Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® : ¿öÅ©Ç÷οì, ¼­ºñ½º, ¼Ö·ç¼Ç, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°
Drug Discovery Informatics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Workflow, Service, Solution, End User, and Geography
»óǰÄÚµå : 1471953
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,263,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 9,078,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 11,893,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀåÀº 2023³â¿¡ 30¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2031³â¿¡´Â 81¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023-2031³â CAGRÀº 13.0%·Î ÃßÁ¤µË´Ï´Ù.

½ÃÀå °³Ã´À» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº Á¦¾à±â¾÷ÀÇ ½Å¾à ºÐÀÚ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ½Å¾à °³¹ß ¹× ¾à¹° °³¹ßÀ» À§ÇÑ °è»ê ¹× Á¤º¸ ÅøÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ±×·¯³ª ¼÷·ÃµÈ ±â¼úÀÚ ºÎÁ·°ú ³ôÀº ¼ÒÇÁÆ®¿þ¾î ¼³Ä¡ ºñ¿ëÀÌ Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå µ¿Çâ :

AI¿Í ¸Ó½Å·¯´×(ML) ¾Ë°í¸®ÁòÀÇ µµÀÔÀº ½Å¾à°³¹ß°ú ¾à¹°°³¹ßÀÇ È¿À²¼º, ¼Óµµ, ¼º°ø·üÀ» Çâ»ó½ÃÅ´À¸·Î½á ½Å¾à°³¹ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¹æ´ëÇÑ ¾çÀÇ µ¥ÀÌÅ͸¦ ºÐ¼®Çϰí, ÆÐÅÏÀ» ½Äº°Çϰí, ºÐÀÚ °£ »óÈ£ ÀÛ¿ëÀ» ¿¹ÃøÇϰí, ½Å¾à Èĺ¸¹°ÁúÀÇ ¹ß°ßÀ» °¡¼ÓÈ­ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. Á¤º¸ °úÇп¡ AI¸¦ µµÀÔÇÔÀ¸·Î½á ¾òÀ» ¼ö ÀÖ´Â ÀÌÁ¡À¸·Î ÀÎÇØ ½Å¾à ºÐÀÚ¸¦ ¹ß°ßÇÏ°í °³¹ßÇϱâ À§ÇÑ °è»ê Åø, ¾Ë°í¸®Áò ¹× µ¥ÀÌÅͺ£À̽º¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇコÄÉ¾î ±â¼ú Á¦Á¶¾÷üµéÀº AI¸¦ ÅëÇÕÇÑ ´Ù¾çÇÑ ¼Ö·ç¼ÇÀ» ½ÃÀå¿¡ Ãâ½ÃÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå ±Ô¸ð È®´ë¿¡ ±àÁ¤ÀûÀ¸·Î ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 12¿ù ¸ÓÅ©(Merck)´Â ½Å¾à°³¹ß°ú ÇÕ¼ºÀ» °áÇÕÇÑ Çõ½ÅÀûÀÎ AI ¼Ö·ç¼ÇÀÎ AIDDISON ½Å¾à°³¹ß ¼ÒÇÁÆ®¿þ¾î¸¦ ¹ßÇ¥Çß´Ù°í ¹àÇû½À´Ï´Ù. ÀÌ´Â Synthia retrosynthesis ¼ÒÇÁÆ®¿þ¾îÀÇ API ÅëÇÕÀ» ÅëÇØ °¡»ó ºÐÀÚ ¼³°è¿Í ½ÇÁ¦ Á¦Á¶ °¡´É¼ºÀ» ¿¬°áÇÏ´Â ÃÖÃÊÀÇ SaaS Ç÷§ÆûÀÔ´Ï´Ù.

¶ÇÇÑ ÁÖ¿ä ÇÏÀÌÅ×Å© ±â¾÷Àº Çаè¿Í Çù·ÂÇÏ¿© ½Å¾à°³¹ßÀ» À§ÇÑ Á¤º¸±â¼úÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 1¿ù È÷Ÿġ ÇÏÀÌÅ×Å© ¼Ö·ç¼ÇÁî(Hitachi High-Tech Solutions, Inc.)´Â °ÔÀÌ¿À´ëÇб³ ¾àÇдëÇÐ ¾àÇаú¿Í Çù·ÂÇÏ¿© Àç·á Á¤º¸ÇÐ(Materials Informatics, MI)À» Ȱ¿ëÇÏ¿© ÀúºÐÀÚ ÀǾàǰÀÇ °³¹ß È¿À²À» ³ôÀ̱â À§ÇÑ °øµ¿¿¬±¸¸¦ ÁøÇàÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÆÀÀº ÄɹÌÄÃÁî ÀÎÆ÷¸Åƽ½º(CI)ÀÇ MI ÅøÀ» Ȱ¿ëÇÏ¿© ±âÁ¸ÀÇ È­ÇÐ Àç·á ºÐ¾ß»Ó¸¸ ¾Æ´Ï¶ó »ç¶÷µéÀÇ »îÀÇ Áú(QoL) Çâ»óÀ» ¸ñÇ¥·Î ÇÏ´Â ½Å¾à °³¹ß ºÐ¾ß¿¡¼­µµ Àç·á °³¹ßÀ» ÁøÇàÇÒ ¿¹Á¤ÀÔ´Ï´Ù.

ÀÌ·¯ÇÑ ½Å¾à °³¹ß ¹× Á¦Ç° Ãâ½Ã¿¡ ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ÇâÈÄ ¼ö³â°£ »õ·Î¿î ½Å¾à °³¹ß ÀÎÆ÷¸Åƽ½º ½ÃÀå µ¿ÇâÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå ºÎ¹®º° °³¿ä

¾Ï ºÐ¾ß ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ¾àÈ¿±ºº°, ¾ÏÁ¾º°, À¯Åëä³Îº°·Î ±¸ºÐµË´Ï´Ù.

¿öÅ©Ç÷ο쿡 µû¶ó Drug Discovery ÀÎÆ÷¸Åƽ½º¿Í Ž»ö ÀÎÆ÷¸Åƽ½º ºÎ¹®ÀÌ 2023³â ´õ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Å¾à °³¹ß ºÎ¹®Àº 2023-2031³â ´õ ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÎÆ÷¸Åƽ½º Åø¿Í µ¥ÀÌÅͺ£À̽ºÀÇ µµÀÔÀ¸·Î »õ·Î¿î Ä¡·á¹ýÀ» ½ÃÀå¿¡ Ãâ½ÃÇÏ´Â µ¥ °É¸®´Â ½Ã°£ÀÌ Å©°Ô ´ÜÃàµÇ¾ú½À´Ï´Ù. À̴ ƯÈ÷ ÁöÄ« ¹ÙÀÌ·¯½º³ª ¿ìÇÑ Æó·Å°ú °°Àº ±¹³»¿Ü Àç³­ »óȲ¿¡¼­ »çȸ¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÇöÀç ±â¼úÀ» Á¢ÇÑ °á°ú, ÀÎÆ÷¸Åƽ½º Åø¿Í µ¥ÀÌÅͺ£À̽º´Â ÇâÈÄ ¸î³â¾È¿¡ ¾öû³ª°Ô È®ÀåµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº °øÁߺ¸°Ç ºÐ¾ß¿¡¼­ »õ·Î¿î Ä¡·á¹ýÀ» ã´Â µ¥ ÇʼöÀûÀ̸ç, ÀÌ´Â Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼­ºñ½ºº°·Î ½ÃÀåÀº ½ÃÄö½Ì Ç÷§Æû, ºÐÀÚ ¸ðµ¨¸µ, ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ °ü¸®, µµÅ·, ±âŸ·Î ±¸ºÐµÇ¸ç, 2023³â¿¡´Â ½ÃÄö½Ì Ç÷§Æû ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÐÀÚ ¸ðµ¨¸µ ºÎ¹®Àº 2023-2031³â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼Ö·ç¼Çº°·Î Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀåÀº ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º·Î ±¸ºÐµÇ¸ç, 2023³â Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå Á¡À¯À²Àº ¼­ºñ½º ºÎ¹®ÀÌ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2031³â ´õ ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó ½ÃÀåÀº Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷, °è¾à ¿¬±¸ ±â°ü, ±âŸ·Î ±¸ºÐµË´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ ºÎ¹®ÀÌ 2023³â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °è¾à ¿¬±¸ ±â°ü ºÎ¹®Àº 2023-2031³â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå Áö¿ªÀû °³¿ä

Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå Á¶»ç ¹üÀ§´Â ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ), À¯·´(½ºÆäÀÎ, ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Çѱ¹, Áß±¹, Àεµ, ÀϺ», È£ÁÖ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(³²¾ÆÇÁ¸®Ä«°øÈ­±¹, »ç¿ìµð¾Æ¶óºñ¾Æ, ¾Æ¶ø¿¡¹Ì¸®Æ®, ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«), Áß³²¹Ì(ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì)·Î ³ª´¹´Ï´Ù, »ç¿ìµð¾Æ¶óºñ¾Æ, ¾Æ¶ø¿¡¹Ì¸®Æ®, ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«), Áß³²¹Ì(ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì)ÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2023-2031³â Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå¿¡¼­ °¡Àå ºü¸¥ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Charles River Laboratories, Sartara, Curia¿Í °°Àº ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç, ³ôÀº Àü¿°º´ ¹ß»ý·ü, ÁÖ¿ä Á¦¾à»ç ¹× CRO(Contract Research Organization)°¡ ½Å¾à °³¹ßÀ» À§ÇØ »õ·Ó°í Áøº¸µÈ R&D ÅøÀ» ºü¸£°Ô äÅÃÇϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå ±¸µµ

Á¦5Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

Á¦7Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå - ¸ÅÃ⠺м®, 2021-2031³â : ¿öÅ©Ç÷ο캰

Á¦8Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå - ¸ÅÃ⠺м®, 2021-2031³â : ¼­ºñ½ºº°

Á¦9Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå - ¸ÅÃ⠺м®, 2021-2031³â : ¼Ö·ç¼Çº°

Á¦10Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå - ¸ÅÃ⠺м®, 2021-2031³â : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå - ¸ÅÃ⠺м®, 2021-2031³â : Áö¿ª ºÐ¼®

Á¦12Àå ¾÷°è »óȲ

Á¦13Àå °æÀï ±¸µµ

Á¦14Àå Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå - ÁÖ¿ä ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Drug discovery informatics market was valued at US$ 3.07 billion in 2023 and is expected to reach US$ 8.17 billion by 2031; it is estimated to record a CAGR of 13.0% during 2023-2031.

Key factors driving the market growth are the increasing investments in the R&D of new drug molecules by pharmaceutical companies and the growing adoption of computational and information tools for drug discovery and development. However, the dearth of skilled technicians and the high cost of software setup hinder the drug discovery informatics market growth.

Market Trends of the Drug Discovery Informatics Market:

The deployment of AI and machine learning (ML) algorithms in drug development and discovery are revolutionizing drug development by enhancing these processes' efficiency, speed, and success rates. These technologies are used to analyze vast amounts of data, identify patterns, predict molecular interactions, and accelerate the discovery of novel drug candidates. The advantages offered by incorporating AI in informatics sciences have surged the demand for computational tools, algorithms, and databases to discover and develop new drug molecules. Additionally, healthcare technology manufacturers are launching various AI-integrated solutions in the market; this is positively contributing to the growing drug discovery informatics market size. For instance, as per the company press release, in December 2023, Merck introduced AIDDISON drug discovery software, an innovative AI solution that combines drug discovery and synthesis. It is the first software-as-a-service platform that bridges virtual molecule design and real-world manufacturability through Synthia retrosynthesis software API integration.

Additionally, leading tech companies are collaborating with academic institutions to develop information technology for drug discovery. For instance, in January 2023, Hitachi High-Tech Solutions Corporation announced the partnership with Keio University Faculty of Pharmacy, Department of Pharmaceutical Sciences, to conduct joint research that will use Materials Informatics (MI) to enhance the efficiency of developing small molecule drugs. The team will leverage the Chemicals Informatics (CI) MI tool for developing materials in the traditional chemical materials field and also in drug discovery, with a view to improving the Quality of Life (QoL) for people.

Thus, such technological advancements in drug discovery and product launches are anticipated to bring new drug discovery informatics market trends in the coming years.

Drug Discovery Informatics Market: Segmental Overview

The oncology biosimilars are segmented based on drug class, cancer type, and distribution channel.

By workflow, the market is bifurcated into discovery informatics and drug development. The discovery informatics segment held a larger market share in 2023. The drug development segment is projected to register a higher CAGR from 2023 to 2031. The deployment of informatics tools and databases has significantly reduced the time to market for new therapies. This has remarkably impacted society, especially during national and international disasters, such as the Zika and Wuhan virus outbreaks. As a result of exposure to current technology, informatics tools, and databases are expected to expand enormously in the coming years. These technologies will be essential in helping the public health sector find novel therapies, which, in turn, is anticipated to propel the drug discovery informatics market growth.

The market, by service, is segmented into sequence analysis platforms, molecular modeling, clinical trial data management, docking, and others. The sequence analysis platform segment is anticipated to hold the largest market share in 2023. The molecular modeling segment is projected to register the highest CAGR from 2023 to 2031.

By solution, the drug discovery informatics market is segmented into software and services. The services segment held a larger drug discovery informatics market share in 2023, and the same segment is projected to register a higher CAGR from 2023 to 2031.

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2023. The contract research organizations segment is expected to register the highest CAGR from 2023 to 2031.

Drug Discovery Informatics Market: Geographical Overview

The scope of the drug discovery informatics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the Drug discovery informatics market from 2023-2031. This is attributed to factors such as the presence of major players, including Charles River Laboratories, Certara, and Curia, the high incidence of infectious diseases, and the rapid adoption of new and advanced R&D tools by leading pharmaceutical companies and Contract Research Organizations (CROs) for drug discovery and development.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Drug Discovery Informatics Market Landscape

5. Drug Discovery Informatics Market - Key Market Dynamics

6. Drug Discovery Informatics Market - Global Market Analysis

7. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By Workflow, 2021-2031

8. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By Service, 2021-2031

9. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By Solution, 2021-2031

10. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By End User, 2021-2031

11. Drug Discovery Informatics Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

Note - Similar analysis would be provided for below mentioned regions/countries

12. Industry Landscape

13. Competitive Landscape

14. Drug Discovery Informatics Market - Key Company Profiles

Note - Similar information would be provided for below list of companies

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â